News
IBB
--
0.00%
--
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 1d ago
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 2d ago
Stocks rise as tech shares gain, Nasdaq rebounds from worst week since March
Stocks rose amid a slew of corporate dealmaking activity as the market tried to recover from its first back-to-back weekly declines in months.
CNBC.com · 6d ago
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 6d ago
The Final Trade: IBB, NFLX, PLNT & PTON
The traders offer their final stock picks of the week.
CNBC.com · 09/11 22:20
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)
Benzinga · 09/10 11:20
Buy on the Dip Prospects: September 9 Edition
Here is a look at ETFs that currently offer attractive short buying opportunities. The ETFs included in this list are rated as buy candidates for two reasons. First, each of these funds is deemed to be in an uptrend based on the fact that its 50-day moving average is above its 200-day moving average,
ETF Database · 09/09 23:00
As Political Pressure Mounts, COVID-19 Vaccine Developers Pledge To Put Safety First
Against the backdrop of pressure to expeditiously bring out a coronavirus vaccine as quickly as possible, biopharma companies working on vaccine candidates said as a group Tuesday that safety comes first.
Benzinga · 09/08 21:33
Bond Shorts Burned After Tech Selloff Reignites Treasury Rally
Newly minted bond bears got a harsh lesson in market timing on Tuesday as a precipitous drop in technology shares sent investors in search of havens.
Bloomberg · 09/08 18:53
Blue-Chip ETFs Hold Up During Massive Selloff in Tech Shares
As the brutal technology rout deepens, exchange-traded fund investors are placing bets on value.
Bloomberg · 09/08 15:28
Investors Buying the Dip Pour Billions Into Two Nasdaq Funds
Bloomberg · 09/08 12:27
Hedge Fund’s Buying Spree During Credit Slump Fuels 36% Return
Distressed-assets specialist Alp Ercil went on a billion-dollar buying spree in March and April, bargain-hunting amid the indiscriminate selloff in credit markets, a person familiar with the matter said.
Bloomberg · 09/06 21:00
Passive Investing: The $10,000 Portfolio For Saving Up Down Payment Before 30
Laymen who have little experience should never attempt to pick individual stocks.Instead, they should stick with a passive investing strategy that is statically proven.The do-it-yourself-portfolio beats the major indexes such as the Dow Jones, S&P500, and Nasdaq on a risk-adjusted basis.More importantly, investors simply have to buy-and-hold and rebalance annually to achieve their financial goals.
Seekingalpha · 09/02 21:00
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
marketwatch.com · 08/10 08:27
Biogen's stock rises after big earnings beat, raised outlook
marketwatch.com · 07/22 07:30
Healthcare Dashboard For July
Seeking Alpha - Article · 07/21 16:35
Health care has 'more room to run' after hitting record highs, ETF analyst says
The health-care trade can continue to work as biotechnology and pharmaceutical companies get closer to finding treatments and a possible vaccine for Covid-19, says Todd Rosenbluth, senior director of ETF and mutual fund research at CFRA.
CNBC.com · 07/21 11:54
Immuron's stock pulls back but still nearly doubles after stock offering
marketwatch.com · 07/21 09:00
Gilead Sciences to pay $300 million for nearly half of Tizona, has option to buy the rest for $1.25 billion
marketwatch.com · 07/21 08:43
Investors cheer as two coronavirus vaccine candidates report T-cell responses, but findings are still early stage
marketwatch.com · 07/21 06:25